Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 60

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 60
---
     
 Reflected in   
 Column (a))(3) 
 (#)            |           |
| Equity compensation plans approved by shareholders        |     |               | 11,393,363 |     |               | 12.87 |     |                | 5,179,496 |
| Equity compensation plans not approved by shareholders(4) |     |               |    289,700 |     |               |  8.76 |     |                |   335,300 |
| Total                                                     |     |               | 11,683,063 |     |               | 12.76 |     |                | 5,514,796 |

| (1) | Includes the Pre-IPO Plan and the 2020 Plan, but does not include future rights to purchase common shares under our 2020 Employee Share Purchase Plan (“2020 ESPP”), which depend on a number of factors described in our 2020 ESPP and will not be determined until the end of the applicable purchase period. |

| (2) | The weighted-average exercise price excludes any outstanding RSU awards, which have no exercise price. |

| (3) | Includes the 2020 Plan and 2020 ESPP. Stock options or other share awards granted under the Pre-IPO Plan that are forfeited, terminated, expired or repurchased become available for issuance under the 2020 Plan. In |

42

| accordance with the terms of the 2020 Plan and the 2020 ESPP, the total number of our common shares reserved for issuance thereunder automatically increased on January 1st in an amount equal to 5.0% and 1.0%, respectively, of the total number of shares outstanding on December 31st of the preceding year. Accordingly, on January 1, 2025, the number of our common shares available for issuance under the 2020 Plan and the 2020 ESPP increased by 2,125,535 shares and 425,107 shares, respectively, pursuant to these provisions. These increases are not reflected in the table above. |

| (4) | Reflects: |

| a) | Grants of stock options that were “inducement grants” as defined under Nasdaq Listing Rule 5635(c)(4). Additionally, in April 2024, our board of directors approved the adoption of the 2024 Inducement Plan (the “Inducement Plan”) to be used exclusively for grants of awards to individuals who were